Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
40 hedge funds and large institutions have $11M invested in Checkpoint Therapeutics in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 9 closing their positions.
2.24% more ownership
Funds ownership: 21.4% → 23.63% (+2.2%)
2% more call options, than puts
Call options by funds: $826K | Put options by funds: $809K
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
1% less capital invested
Capital invested by funds: $11.2M → $11M (-$140K)
7% less funds holding
Funds holding: 43 → 40 (-3)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$737K |
| 2 |
AC
Armistice Capital
New York
|
+$578K |
| 3 |
Renaissance Technologies
New York
|
+$210K |
| 4 |
Millennium Management
New York
|
+$103K |
| 5 |
CL
Choreo LLC
Rockford,
Illinois
|
+$77.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$228K |
| 2 |
Jane Street
New York
|
-$92.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$77.1K |
| 4 |
Wealth Enhancement Advisory Services
Plymouth,
Minnesota
|
-$69.8K |
| 5 |
D.E. Shaw & Co
New York
|
-$63.7K |
CKPT Hedge Fund Activity: Q1 2024 in Review
40 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q1 2024, worth a combined $11M — down 1.3% from $11.2M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CKPT and 8 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 12 added.
The largest buyer was Vanguard Group, adding an estimated $737K. The largest seller was B. Riley Wealth Advisors, cutting an estimated $228K.
- 40 institutional investors held Checkpoint Therapeutics (CKPT) as of Q1 2024, down from 43 in Q4 2023.
- Funds reported $11M of Checkpoint Therapeutics stock for Q1 2024, down 1.3% quarter-over-quarter.
- 8 funds opened new Checkpoint Therapeutics positions in Q1 2024 and 9 closed out, a net change of -1 holder.
- The largest Checkpoint Therapeutics buyer in Q1 2024 was Vanguard Group, an estimated $737K added.
- The largest Checkpoint Therapeutics seller in Q1 2024 was B. Riley Wealth Advisors, an estimated $228K sold.
Based on aggregated 13F filings for Q1 2024.